Ser546

Site Information
sMsEFLEsEDGEVEQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449173

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 7 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ) , mutation of modification site ( 7 ) , phospho-antibody ( 7 ) , western blotting ( 7 )
Disease tissue studied:	breast cancer ( 6 , 11 , 17 ) , breast ductal carcinoma ( 11 ) , HER2 positive breast cancer ( 4 ) , luminal A breast cancer ( 4 ) , luminal B breast cancer ( 4 ) , breast cancer, surrounding tissue ( 4 ) , breast cancer, triple negative ( 4 , 11 ) , cervical cancer ( 29 ) , cervical adenocarcinoma ( 29 ) , leukemia ( 21 , 37 ) , acute myelogenous leukemia ( 21 ) , chronic myelogenous leukemia ( 37 ) , lung cancer ( 9 , 13 , 17 , 26 ) , non-small cell lung cancer ( 17 ) , non-small cell lung adenocarcinoma ( 9 , 13 ) , lymphoma ( 12 ) , Burkitt's lymphoma ( 12 ) , follicular lymphoma ( 12 ) , mantle cell lymphoma ( 12 ) , ovarian cancer ( 11 ) , melanoma skin cancer ( 8 )
Relevant cell line - cell type - tissue:	293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 38 ) , 293 (epithelial) [AT1 (human), transfection] ( 27 ) , 293 (epithelial) ( 32 ) , 293E (epithelial) ( 22 ) , A549 (pulmonary) ( 14 ) , BJAB (B lymphocyte) ( 12 ) , breast ( 4 , 11 ) , BT-20 (breast cell) ( 17 ) , BT-474 (breast cell) ( 6 ) , BT-549 (breast cell) ( 17 ) , Calu 6 (pulmonary) ( 17 ) , CL1-0 (pulmonary) ( 26 ) , CL1-1 (pulmonary) ( 26 ) , CL1-2 (pulmonary) ( 26 ) , CL1-5 (pulmonary) ( 26 ) , endothelial-aorta ( 18 ) , FL-18 (B lymphocyte) ( 12 ) , FL-318 (B lymphocyte) ( 12 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 19 ) , Flp-In T-Rex-293 (epithelial) ( 19 ) , GM00130 (B lymphocyte) ( 28 ) , H2009 (pulmonary) ( 17 ) , H2077 (pulmonary) ( 17 ) , H2887 (pulmonary) ( 17 ) , H322M (pulmonary) ( 17 ) , HCC2279 (pulmonary) ( 17 ) , HCC366 (pulmonary) ( 17 ) , HCC78 (pulmonary) ( 17 ) , HCC827 (pulmonary) ( 17 ) , HEK293T (epithelial) ( 7 ) , HeLa (cervical) ( 3 , 10 , 16 , 25 , 33 , 34 , 36 , 38 , 39 , 40 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 23 ) , HeLa S3 (cervical) ( 23 , 29 ) , HOP62 (pulmonary) ( 17 ) , HUES-7 ('stem, embryonic') ( 31 ) , HUES-9 ('stem, embryonic') ( 24 ) , JHOC-5 ( 1 ) , Jurkat (T lymphocyte) ( 15 , 35 ) , K562 (erythroid) ( 16 , 30 , 37 ) , KG-1 (myeloid) ( 21 ) , LCLC-103H (pulmonary) ( 17 ) , LOU-NH91 (squamous) ( 17 ) , lung ( 13 ) , MCF-7 (breast cell) ( 6 ) , MDA-MB-231 (breast cell) ( 17 ) , MDA-MB-468 (breast cell) ( 17 ) , NCEB-1 (B lymphocyte) ( 12 ) , NCI-H1395 (pulmonary) ( 17 ) , NCI-H1568 (pulmonary) ( 17 ) , NCI-H157 (pulmonary) ( 17 ) , NCI-H1648 (pulmonary) ( 17 ) , NCI-H1666 (pulmonary) ( 17 ) , NCI-H2030 (pulmonary) ( 17 ) , NCI-H2172 (pulmonary) ( 17 ) , NCI-H322 (pulmonary) ( 17 ) , NCI-H460 (pulmonary) ( 17 ) , NCI-H520 (squamous) ( 17 ) , NCI-H647 (pulmonary) ( 17 ) , ovary ( 11 ) , PC9 (pulmonary) ( 9 , 17 ) , PC9-IR (pulmonary) ( 9 ) , Raji (B lymphocyte) ( 12 ) , RAMOS (B lymphocyte) ( 12 ) , SU-DHL-4 (B lymphocyte) ( 12 ) , UPN-1 (B lymphocyte) ( 12 ) , Vero E6-S ('epithelial, kidney') ( 2 ) , WM239A (melanocyte) ( 8 )

Upstream Regulation
Regulatory protein:	SMARCA4 (human) ( 1 )
Kinases, in vitro:	PLK1 (human) ( 7 )
Treatments:	BI2536 ( 25 ) , nocodazole ( 29 )

Downstream Regulation
Effects of modification on SUZ12:	molecular association, regulation ( 7 ) , ubiquitination ( 7 )
Inhibit interaction with:	EZH2 (human) ( 7 )

References
1	Kimura A, et al. (2021) Phosphorylation of Ser1452 on BRG1 inhibits the function of the SWI/SNF complex in chromatin activation. J Proteomics 247, 104319 34237461 Curated Info
2	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
3	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
4	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
5	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
6	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
7	Zhang H, et al. (2015) PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis. Cancer Res 75, 2363-74 25855382 Curated Info
8	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
9	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
10	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
11	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
12	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
13	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
14	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
15	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
16	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
17	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
18	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
19	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
20	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
21	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
22	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
23	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
24	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
25	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
26	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
27	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
28	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
29	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
30	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
31	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
32	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
33	Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20 19351860 Curated Info
34	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
35	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
36	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
37	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
38	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
39	Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51 18220336 Curated Info
40	Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5 15302935 Curated Info